Christopher Van Tuyl net worth and biography

Christopher Van Tuyl Biography and Net Worth

Chief Legal Officer and Corporate Secretary of Immunovant

Chris Van Tuyl brings over 25 years of legal experience to Immunovant. He most recently served as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in Immuno-Dermatology. Prior to joining Dermavant, Mr. Van Tuyl was a corporate partner at the law firm Sacks Tierney P.A., where his practice focused on the healthcare, pharmaceutical, and technology industries. He previously served in various in-house legal positions at publicly traded companies, including as Legal Executive at FIS Global, Corporate Secretary and Chief Compliance Officer at Rayonier Inc., and Associate General Counsel at Medicis Pharmaceutical Corporation. Mr. Van Tuyl began his legal career in private practice as a corporate attorney at the international law firms of Squire, Sanders & Dempsey LLP in Phoenix and Clifford Chance LLP in New York.

He received his J.D. from Duke University School of Law and his B.S. in Finance summa cum laude from Arizona State University.

What is Christopher Van Tuyl's net worth?: The estimated net worth of Christopher Van Tuyl is at least $3.90 million as of December 18th, 2025. Mr. Van Tuyl owns 149,930 shares of Immunovant stock worth more than $3,898,180 as of February 1st. This net worth estimate does not reflect any other investments that Mr. Van Tuyl may own. Learn More about Christopher Van Tuyl's net worth.
How do I contact Christopher Van Tuyl?: The corporate mailing address for Mr. Van Tuyl and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Christopher Van Tuyl's contact information.
Has Christopher Van Tuyl been buying or selling shares of Immunovant?: Christopher Van Tuyl has not been actively trading shares of Immunovant during the last ninety days. Most recently, Tuyl Christopher Van sold 10,813 shares of the business's stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $26.91, for a transaction totalling $290,977.83. Following the completion of the sale, the insider now directly owns 149,930 shares of the company's stock, valued at $4,034,616.30. Learn More on Christopher Van Tuyl's trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Andrew Fromkin (Director), Michael Geffner (Chief Medical Officer), Melanie Gloria (COO), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), Frank Torti (Director), and Christopher Van Tuyl (Chief Legal Officer and Corporate Secretary). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 16,666,666 shares worth more than $349,999,986.00. During the last twelve months, insiders at the sold shares 20 times. They sold a total of 131,391 shares worth more than $2,576,181.09. The most recent insider tranaction occured on January, 21st when CTO Jay S Stout sold 1,977 shares worth more than $51,461.31. Insiders at Immunovant own 1.8% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 1/21/2026.

Christopher Van Tuyl Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/18/2025	Sell	10,813	$26.91	$290,977.83	149,930

Christopher Van Tuyl Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $26.00

$25.42

$26.42

50 Day Range

MA: $25.43

$22.02

$27.54

2 Week Range

Now: $26.00

$12.72

$27.80

Volume

1,825,430 shs

Average Volume

1,432,062 shs

Market Capitalization

$4.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57